PTC Therapeutics | PTCT - Debt


PTC Therapeutics reported $286.32M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Cytokinetics USD 1.2B 338.79M Sep/2025
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Gilead Sciences USD 24.94B 5M Sep/2025
Incyte USD 40.41M 855K Dec/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 264.09M 39.31M Sep/2024
Novartis USD 32.64B 1.37B Jun/2025
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025
Xencor USD 67.93M 86.45M Jun/2025